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SCIENTIFIC OPINION 
Scientific Opinion on the safety and efficacy of Bonvital (Enterococcus 
faecium) for chickens reared for laying and minor avian species
1 
EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP)
2,3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Bonvital is a preparation of a strain of Enterococcus faecium authorised for use in piglets and pigs for fattening, 
in sows and in chickens for fattening. The applicant is seeking the further authorisation of Bonvital for use in 
chickens reared for laying and minor avian species. The E. faecium strain does not contain marker genes typical 
of  hospital-associated  isolates  responsible  for  clinical  infections  and  is  susceptible  to  clinically  relevant 
antibiotics. The safety of Bonvital in chickens for fattening has been established in a previous assessment. Since 
the applicant proposes the use of the same dose (5   10
8 CFU/kg complete feedingstuffs) in chickens reared for 
laying, safety for this animal category can be presumed. As the same dose is proposed for minor avian species, 
this conclusion can be extrapolated to minor avian species to point of lay. The strain is not expected to raise 
concerns for consumers of animal products. Bonvital is not irritant to skin and eyes. In the absence of data, it 
should be considered to have the potential to be a skin/respiratory sensitiser and treated accordingly. The use of 
Bonvital under the conditions proposed is considered safe for the environment. The efficacy in chickens for 
fattening has been established in a previous assessment. Since the applicant proposes the use of the same dose (5 
 10
8 CFU/kg complete feedingstuffs) in chickens reared for laying, the conclusion on the major species can be 
extended to this category. As the same dose is proposed for minor avian species and as the mechanism of action 
of the additive can reasonably be assumed to be the same as in the major species, efficacy in minor avian species 
to point of lay can be presumed. 
© European Food Safety Authority, 2013   
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SUMMARY 
Following a request from the European Commission, the European Food Safety Authority was asked 
to  deliver  a  scientific  opinion  on  the  safety  and  efficacy  of  Bonvital  (Enterococcus  faecium)  in 
chickens reared for laying and minor avian species. This product is authorised for use in piglets, pigs 
for fattening, sows and chickens for fattening. The Enterococcus faecium strain in combination with a 
Lactobacillus rhamnosus strain is also authorised for use in calves and piglets.  
The strain does not contain marker genes typical of hospital-associated isolates responsible for clinical 
infections and is susceptible to clinically relevant antibiotics. 
The safety in chickens for fattening has been established in a previous assessment. Consequently, the 
conclusions on the safety in chickens for fattening can be extended to chickens reared for laying and 
extrapolated to minor poultry species to point of lay at the maximum dose of 5   10
8 CFU/kg feed. 
Since the strain does not belong to the hospital-associated clade and does not express resistance to the 
antibiotics tested, use of this strain of Bonvital in animal nutrition is not expected to raise concerns for 
consumers of animal products. 
Bonvital is not irritant to skin and eyes. In the absence of data, it should be considered to have the 
potential to be a skin/respiratory sensitiser and treated accordingly. The powder form of Bonvital has 
the potential to produce dust containing a large number of particles of respirable size. In the absence of 
information  on  the  acute  inhalation  toxicity  of  this  additive,  it  would  be  prudent  to  regard  the 
respirable  dust  as  potentially  harmful  to  workers  and  appropriate  measures  should  be  taken  to 
minimise operator exposure to dust. 
E. faecium is a natural component of gut microbiota and its use as Bonvital in animal feeding would 
not be expected to pose any risk to the environment. 
The  efficacy  in  chickens  for  fattening  has  been  established  in  a  previous  assessment.  Since  the 
applicant proposes the use of the same dose (5   10
8 CFU/kg complete feedingstuffs) in chickens 
reared for laying, the conclusion on chickens for fattening can be extended to chickens reared for 
laying. As the same dose is proposed for minor avian species and as the mechanism of action of the 
additive can reasonably be assumed to be the same as in the major species, efficacy in minor avian 
species to point of lay can be presumed.  Bonvital for chickens for laying and minor avian species 
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BACKGROUND  
Regulation  (EC)  No  1831/2003
4  establishes the rules governing the Community authorisation of 
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any 
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an 
application in accordance with Article 7.  
The European Commission received a req uest from the company  Lactosan GmbH & Co.KG
5 for 
authorisation of the product  Bonvital,  (Enterococcus  faecium),  when  used  as  a  feed  additive  for 
chickens reared for laying and minor avian species (category: zootechnical additive; functional group: 
gut flora stabiliser) under the conditions mentioned in Table 1.  
According  to  Article  7(1)  of  Regulation  (EC)  No  1831/2003,  the  Commission  forwarded  the 
application  to  the  European  Food  Safety  Authority  (EFSA)  as  an  application  under  Article  4(1) 
(authorisation of a feed additive or new use of a feed additive). EFSA received directly from the 
applicant  the  technical  dossier  in  support  of  this  application.
6  According  to  Article  8  of  that 
Regulation, EFSA, after verifying the particulars and documents submitted by t he applicant, shall 
undertake an assessment in order to determine whether the feed additive complies with the conditions 
laid down in Article 5. The particulars and documents in support of the application were considered 
valid by EFSA as of 20 April 2011. 
The additive Bonvital is a preparation of  Enterococcus  faecium  (DSM  7134).  This  product  is 
authorised for use in piglets and pigs for fattening, sows, and chickens for fattening (4b1841). The 
strain Enterococcus faecium (DSM 7134) in combination with Lactobacillus rhamnosus (DSM 7133) 
is also authorised for calves and piglets (E1706). 
The Scientific Committee on Animal Nutrition (SCAN) issued an opinion on the safety for pigs for 
fattening  and  calves,  the  consumer,  user  and  environment  of  a  microbial  product  containing 
Enterococcus faecium (DSM 7134) and Lactobacillus rhamnosus (DSM 7133) (EC, 1997, updated 
2003) and another opinion on the safety of Enterococcus faecium (DSM 7134) for piglets, pigs for 
fattening and sows (EC, 2003). EFSA published an opinion on the safety of Bonvital (Enterococcus 
faecium DSM 7134) for chickens for fattening (EFSA, 2004), an opinion on the safety and efficacy for 
piglets and pigs for fattening (EFSA, 2007a), an opinion on the safety and efficacy for sows (EFSA, 
2007b), and two opinions on Bonvital when used as a feed additive in chickens for fattening (EFSA, 
2009 and 2010). 
TERMS OF REFERENCE  
According to Article 8 of Regulation (EC) No 1831/2003, EFSA shall determine whether the feed 
additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the 
safety for the target animals, consumer, user and the environment and the efficacy of the product 
Bonvital (Enterococcus faecium), when used under the conditions described in Table 1. 
                                                       
4   Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use 
in animal nutrition. OJ L 268, 18.10.2003, p. 29. 
5   Lactosan GmbH & Co.KG. Industriestrasse West 5, 8605 Kapfenberg, Austria. 
6   EFSA Dossier reference: FAD-2011-0012. Bonvital for chickens for laying and minor avian species 
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Table 1:  Description and conditions of use of the additive as proposed by the applicant  
Additive   Enterococcus faecium DSM 7134 
Registration number/EC 
No/No  
4b1841 
Category(-ies) of additive  Zootechnical additive 
Functional group(s) of additive  Gut flora stabiliser 
 
Description 
Composition, description  Chemical 
formula 
Purity criteria 
 
Method of analysis 
 
Preparation of Enterococcus 
faecium containing a minimum 
content of: 
 
Powder: 1x10
10 CFU/g additive 
 
Granules (micro-encapsulated): 
1x10
10 CFU/g additive 
 
Impurities: 
Fungi < 100 CFU/g 
Clostridia < 10 CFU/g 
Enterobacteria <10 
CFU/g 
Salmonella not 
detectable in 25 g 
Quantification of 
lactic acid bacteria content 
(Code of the method: LAC-
DO-EF-1a) 
 
Trade name   Bonvital 
Name of the holder of 
authorisation  
Lactosan GmbH & Co.KG 
 
Conditions of use 
Species or 
category of animal 
Maximum 
Age 
Minimum content  Maximum content  Withdrawal 
period 
  CFU/kg of complete feedingstuffs 
Chickens reared 
for laying  
 
 
 
Minor avian 
species 
 
22 
weeks/to 
point of lay 
5 x 10
8     
 
Other provisions and additional requirements for the labelling 
Specific conditions or restrictions for 
use  
Can  be  used  with  the  following  coccidiostats:  Deccox,  Stenorol, 
Avatec 150G, Elancoban G200, Cycostat 66G, Cygro 1%, Clinacox 
0.6% 
Specific conditions or restrictions for 
handling   The directions for use must indicate storage temperature, shelf life 
Post-market monitoring  
 
Lactosan GmbH & Co.Kg will conduct post-market monitoring in 
compliance  with  EU  law  on  feed  hygiene,  namely  by  use  of 
HACCP  and  treaceability  systems,  and  formal  monitoring  of 
customer feedback through product or service complaints. 
Specific conditions for use in 
complementary feedingstuffs  
 
The directrons for use must indicate pelleting stability both of the 
additive and the premixure 
 
Maximum Residue Limit (MRL)  
Marker residue  Species or category of 
animal 
Target tissue(s) or 
food products 
Maximum content in 
tissues Bonvital for chickens for laying and minor avian species 
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ASSESSMENT 
1.  Introduction 
The  additive  Bonvital  is  a  preparation  of  Enterococcus  faecium  (DSM  7134).  This  product  is 
authorised  for  use  in  piglets,  pigs  for  fattening,  sows  and  chickens  for  fattening.  The  strain 
Enterococcus faecium (DSM 7134) in combination with Lactobacillus rhamnosus (DSM 7133) is also 
authorised for calves and piglets. 
The current dossier contains data supporting a request for authorisation for use of Bonvital as a feed 
additive (zootechnical additive; functional group: gut flora stabiliser) for chickens reared for laying 
and minor avian species.  
2.  Characterisation 
2.1.  Characterisation of the active agent 
Enterococcus faecium DSM 7134 was originally isolated from plant material. The strain is deposited 
in the Deutsche Sammlung von Mikroorganismen und Zellkulturen, under the accession number DSM 
7134.
7 The strain is not genetically modified. 
E. faecium DSM 7134 has been identified by means of biochemical and genetic techniques, such as 
the sequence of the rrn operon, including the 16S rRNA gene, and characterised at strain level by 
pulsed-field  gel  electrophoresis  (PFGE)  and  random  amplification  of  polymorphic  DNA  (RAPD) 
fingerprinting techniques. RAPD and PFGE profiles were used to assess identity of production strain, 
and to compare it with the master cell bank culture.
8  
2.1.1.  Virulence 
In a first set of experiments E. faecium DSM 7134 was demonstrated to be free of the following genes 
encoding putative enterococcal virulence factors by polymerase chain reaction (PCR): the gene for the 
surface protein Esp, located in the E. faecium pathogenicity island, the E. faecalis cytolysin operon, 
the aggregation protein gene agg and the gelatinase gene gelE.
9 
The  applicant  provided  a  new  study,  according  to  the  guidance  on  the  safety  assessment  of 
Enterococcus  faecium  in  animal  nutrition  (EFSA,  2012a).  The  minimum  inhibitory  concentration 
(MIC) of ampicillin for E. faecium DSM 7134 was 0.5 mg/L and the PCR analyses demonstrated the 
absence  of  the  genetic  determinants  IS16,  hylEfm  and  esp,  typical  of  hospital-associated  strains. 
Therefore, the FEEDAP Panel concludes that E. faecium DSM 7134 does not contain marker genes 
typical of hospital-associated isolates responsible for clinical infections. 
2.1.2.  Antimicrobial susceptibility 
The  strain  was tested  for  antibiotic  susceptibility  using  two-fold  broth  dilutions.
10  The battery of 
antibiotics tested included all of th ose recommended by EFSA (EFSA, 2012 b). As all  MIC values 
were  lower  than  the  corresponding  cut -off  values  defined  by  the  FEEDAP  Panel,  no  further 
investigation is required.  
2.2.  Characterisation of the product 
Bonvital is produced by fermentation in a culture medium containing dextrose, whey powder, yeast 
extract and mineral salts. Cells are recovered by centrifugation and washed prior to drying either by 
                                                       
7  Technical dossier/Section II/Annex II.2-1. 
8  Technical dossier/Section II and Supplementary information Jul12/Annexes II.2-2, II.2-316 sRNA, PFGE and RAPD PCR. 
9  Technical dossier/Section II and Supplementary information Jul12/Annexes II.2-4, II.2-5 and virulence. 
10   Technical dossier/Supplementary information Jul12/Annex Antibiotics. Bonvital for chickens for laying and minor avian species 
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freeze-drying or by spraying onto a carrier in a fluidised bed dryer and coated. These two treatments 
lead, respectively, to:  
  Bonvital powder, a mixture of E. faecium DSM 7134 (3 %) with sweet whey powder (96 %), 
lactose, sodium glutamate, sodium ascorbate, sodium lactate and mannose as excipients with a 
minimum guaranteed concentration of 1   10
10 CFU/g product;  
  Bonvital  granules  (micro-encapsulated),  a  mixture  of  E.  faecium  DSM  7134  (3 %)  with 
saccharose (70 %), maltodextrin (20 %) sodium citrate, sodium glutamate, sodium ascorbate, 
sodium  lactate  and  mannose  as  excipients  with  a  minimum  guaranteed  concentration  of 
1   10
10 CFU/g product; 
Compliance  with  the  minimal  concentration  of  the  active  agent  E.  faecium  DSM  7134  (1   
10
10 CFU/g) was demonstrated in a test involving 10 production batches of granular formulation.
11  
Analytical data from  six  batches showed  concentrations of heavy metals (Pb, Hg, Cd), As and 
mycotoxins (aflatoxins B1, B2, G1, G2, desoxynivalenol, zearalenone and ochratoxin A) well below the 
specified concentrations at which corrective action would be required.  The numbers of clostridia, 
Salmonella, Escherichia coli and other microbial contaminants were below detection levels.
12 
Bonvital powder had a mean particle  diameter of 80.1 µm, with approximately 10 % of particles of 
10 µm diameter or less, and a dusting potential of 1.15 g/m
3 as determined by the Stauber–Heubach 
method.
13 Bonvital granules had a mean particle size of 920 µm, with no particles less than 250 µm, 
and a dusting potential of 0.02 g/m
3. 
2.3.  Stability and homogeneity  
The stability of Bonvital was investigated in a long-term storage experiment by examining the colony 
count of the additive when stored at 4 °C, 20 °C, and 37 °C in its original packaging.
14 Data from one 
batch of each form (powder and granules) indicate that the product is stable over  12 months at 4 °C 
and 20 ºC and over six months at 37 °C.  
Stability in two premixtures for pigs containing vitamins and minerals over a period of six months was 
assessed by bacterial count of the active agent for both forms of the product.
15 The batches were stored 
at 20 ºC under dry conditions and protected from light. The product is stable over six months without 
significant losses in the viability of the active agent. 
Stability in feed was investigated in a complete feed and a complementary feed for pigs.
16 Analysis of 
a single batch of both formulations of the additive supports evidence of stability over a period of four 
months when stored at 20 °C in aluminium polyethylene sealed bags. Similar results were seen with 
pelleted pig feed over the same storage period. These results were supported in a shorter-term stability 
study using mash poultry feed made over two months only.  
Stability of Bonvital to pelleting was tested in a study  in which  three batches of the granulate d 
formulation were mixed with a feed for piglets under practical conditions at a temperature of pelleting 
of 70–72 °C.
17 In the pelleted feed a recovery rate of 85 % of the E. faecium cell count was observed.  
The ability of Bonvital to form homogeneous mixtures was demonstrated in a variety of premixtures 
and feeds. Coefficients of variation were all below 10 %.
18 
                                                       
11   Technical dossier/Section II/Annexes II.1-4 and Annex II.1-5. 
12   Technical dossier/Section II/Annexes II.1-6, II.1-7 and Annex II.1-8. 
13   Technical dossier/Section II/Annexes III.1-2, III.3-1 and Annex III.3-2. 
14   Technical dossier/Section II/Annex II.4-1. 
15   Technical dossier/Section II/Annex II.4-4. 
16   Technical dossier/Section II/Annex II.4-5. 
17   Technical dossier/Supplementary information December 2012/Trial pelleting stability. Bonvital for chickens for laying and minor avian species 
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3.  Conditions of use  
The product is intended for use in feed for chickens reared for laying and minor avian species at a 
minimum dose of 5   10
8 CFU/kg complete feedingstuffs.  
4.  Evaluation of the analytical methods by the European Union Reference Laboratory 
(EURL) 
The EURL considered that the conclusions and recommendations reached in the previous assessment 
are valid and applicable for the current application.
19  
5.  Safety 
5.1.  Safety for the target species 
The safety for chickens for fattening has been established in a previous assessment (EFSA, 2010). The 
FEEDAP Panel considers that the conclusions reached in chickens for fattening can be extended to 
chickens reared for laying and extrapolated to all minor avian species to point of lay at the same dose 
(5   10
8
 CFU/kg complete feedingstuffs).  
5.2.  Safety for the consumer 
E.  faecium  DSM  7134  does  not  contain  marker  genes  typical  of  hospital-associated  isolates 
responsible for clinical infections and does not harbour acquired genes coding for antibiotic resistance.  
The  metabolic  pathways  of  E.  faecium  are  well  known  and,  when  the  potential  for  infection  is 
excluded,  no  other  harmful  metabolites  or  substances  are  expected  to  be  produced  during 
fermentation. The additive does not contain excipients of concern. Consequently, the FEEDAP Panel 
does not see the need for toxicological studies and concludes that the additive is safe for consumers. 
5.3.  Safety for the user 
A Good Laboratory Practice (GLP)-compliant study was performed according to  Organisation for 
Economic Co-operation and Development (OECD) Guideline 404 using the Bonvital active agent. A 
dose of 0.5 g of E. faecium DSM 7134 (1   10
10 CFU/g) was applied to the skin of three New Zealand 
White rabbits under a semi-occlusive dressing for four hours.
20 No erythema or oedema was seen in 
observations at 1, 24, 48 and 72 hours after the end of treatment. It is concluded that the test material 
is non-irritant to skin. 
A GLP-compliant study was performed according to OECD Guideline 405  using the Bonvital active 
agent.
21 A dose of 0.1 g of  E. faecium DSM 7134 (1   10
10 CFU/g) was applied to the eye of three 
New Zealand White rabbits. All animals showed redness of the conjunctiva after dosing, with some 
animals also showing mild chemosis or slight discharge. At 72 hours after dosing these effects were no 
longer  apparent  and  corneal  examination  showed  no  lesions.  These  results  indicate  that  the  test 
material should be regarded as non-irritant to eyes and that it does not need to be classified as an eye 
irritant under Directive 93/21 EEC.
22 
Skin sensitisation potential was not studied. Therefore, owing to its proteinaceous nature, it would be 
prudent to consider Bonvital as a potential skin and respiratory sensitiser.  
                                                                                                                                                                      
18   Technical dossier/Section II/Annexes II.4-4 and II.4-5. 
19   The full report is available on the EURL website:  http://irmm.jrc.ec.europa.eu/SiteCollectionDocuments/FinRep-FAD-
2008-0007.pdf 
20   Technical dossier/Section III/ Annex III.3-3. 
21   Technical dossier/Section III/ Annex III.3-4. 
22   Commission Directive 93/21/EEC of 27 Ap ril 1993 adapting to technical progress for the 18th time Council Directive 
67/548/EEC on the approximation of the laws, regulations and administrative provisions relating to the classification, 
packaging and labelling of dangerous substances. OJ L 110, 4.5.1993, pp. 20–21. Bonvital for chickens for laying and minor avian species 
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The data on dusting potential indicate that Bonvital powder has the potential to form dust containing a 
large number of particles of respirable size, whereas Bonvital granules would not form dust containing 
respirable particles when handled normally. In the absence of information  on the acute inhalation 
toxicity of Bonvital powder, it would be prudent to regard the respirable dust as potentially harmful to 
worker,s and appropriate measures should be taken to minimise operator exposure to dust. 
5.4.  Safety for the environment 
E. faecium is a natural component of gut microbiota and its use as Bonvital in animal feeding would 
not be expected to pose any risk to the environment. 
6.  Efficacy  
6.1.  Efficacy for chickens reared for laying  
The efficacy in chickens for fattening has been established in a previous assessment (EFSA, 2010). 
The FEEDAP Panel considers that the conclusions reached regarding chickens for fattening can be 
extended to chickens reared for laying at the same dose (5   10
8 CFU/kg complete feedingstuffs). 
6.2.  Efficacy for minor avian species 
Since efficacy has been shown in chickens for fattening and the mode of action can reasonably be 
assumed to be the same in minor poultry species, the FEEDAP Panel considers that the conclusions 
reached in chickens for fattening can be extrapolated to minor poultry species to point of lay at the 
same dose (5   10
8 CFU/kg complete feedingstuffs). 
6.3.  Compatibility with coccidiostats 
Compatibility  with  robenidine  hydrochloride,  maduramicin  ammonium,  diclazuril,  decoquinate, 
halofuginone hydrobromide, lasalocid A sodium and monensin sodium was established for chickens 
for fattening (EFSA, 2009). This compatibility can reasonably be assumed to apply to the use of the 
additive in chickens reared for laying and minor avian species at the same dose (5   10
8 CFU/kg 
complete feedingstuffs). 
7.  Post-market monitoring  
The  FEEDAP  Panel  considers  that  there  is  no  need  for  specific  requirements  for  a  post-market 
monitoring  plan  other  than  those  established  in  the  Feed  Hygiene  Regulation
23  and  Good 
Manufacturing Practice. 
CONCLUSIONS 
E.  faecium  DSM  7134  does  not  contain  marker  genes  typical  of  hospital-associated  isolates 
responsible for clinical infections and is susceptible to antibiotics of clinical relevance. 
Based on the tolerance study with chickens for fattening previously assessed, the FEEDAP Panel 
concludes that Bonvital is safe for chickens reared for laying. This conclusion can be taken to apply 
also to minor avian species (other than those used for laying).  
Since the strain does not belong to the hospital-associated clade and does not express resistance to the 
antibiotics tested, use of this strain of Bonvital in animal nutrition is not expected to raise concerns for 
consumers of animal products. Since neither the active agent nor the other components of the additive 
give rise to concerns, the FEEDAP Panel considers the use of the additive safe for consumers. 
                                                       
23   Regulation  (EC)  No  183/2005  of  the  European  Parliament  and  of  the  Council  of  12  January  2005  laying  down 
requirements for feed hygiene. OJ L 35, 8.2.2005, p. 1. Bonvital for chickens for laying and minor avian species 
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Bonvital  is  not  irritant  to  skin  and  eyes.  It  should  be  considered  to  have  the  potential  to  be  a 
skin/respiratory sensitiser and treated accordingly. As Bonvital powder has the potential to produce a 
respirable dust, it is considered more hazardous for users than the granular form.  
The use of Bonvital under the conditions proposed is considered safe for the environment. 
The efficacy of Bonvital was demonstrated in chickens for fattening at the dose of 5   10
8 CFU/kg 
complete feedingstuffs. This conclusion can be extended to chickens for laying and extrapolated to 
minor avian species to point of lay.  
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2012. Submitted by Lactosan GmbH & Co.KG  
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